Expression of aldo-keto reductase family 1 member C3 (AKR1C3) in neuroendocrine tumors & adenocarcinomas of pancreas, gastrointestinal tract, and lung

International Journal of Clinical and Experimental Pathology

Volumn 6, Issue 11, 2013, Pages 2419-2429

  Chang, Theodore S ^a   Lin, Hsueh Kung ^a   Rogers, Kyle A ^a   Brame, Lacy S ^b   Yeh, Matthew M ^c   Yang, Qing ^a   Fung, Kar Ming ^a,b,d  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Adenocarcinomas; Aldo keto reductase family 1 member C3 (AKR1C3); Gastrointestinal tract; Immunohistochemistry; Lung; Neuroendocrine tumors; Pancreas

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; 3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; AKR1C3 PROTEIN, HUMAN; TUMOR MARKER;

ADENOCARCINOMA; ADENOCARCINOMAS; ALDO-KETO REDUCTASE FAMILY 1 MEMBER C3 (AKR1C3); ARTICLE; ENZYMOLOGY; GASTROINTESTINAL TRACT; GASTROINTESTINAL TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG; LUNG TUMOR; NEUROENDOCRINE TUMOR; PANCREAS; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS;

ADENOCARCINOMAS; ALDO-KETO REDUCTASE FAMILY 1 MEMBER C3 (AKR1C3); GASTROINTESTINAL TRACT; IMMUNOHISTOCHEMISTRY; LUNG; NEUROENDOCRINE TUMORS; PANCREAS;

3-HYDROXYSTEROID DEHYDROGENASES; ADENOCARCINOMA; GASTROINTESTINAL NEOPLASMS; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84887093771     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Jez JM, Flynn TG and Penning TM. A new nomenclature for the aldo-keto reductase superfamily. Biochem Pharmacol 1997;54:639-647.
2. Jez JM, Bennett MJ, Schlegel BP, Lewis M and Penning TM. Comparative anatomy of the aldo-keto reductase superfamily. Biochem J 1997;326:625-636.
3. Hyndman D, Bauman DR, Heredia VV and Penning TM. The aldo-keto reductase superfamily homepage. Chem Biol Interact 2003;143-144:621-631.
4. Hara A, Matsuura K, Tamada Y, Sato K, Miyabe Y, Deyashiki Y and Ishida N. Relationship of human liver dihydrodiol dehydrogenases to hepatic bile-acid-binding protein and an oxidoreductase of human colon cells. Biochem J 1996;313:373-376.
5. Dufort I, Soucy P, Labrie F and Luu-The V. Molecular cloning of human type 3 3a-hydroxysteroid dehydrogenase that differs from 20a-hydroxysteroid dehydrogenase by seven amino acids. Biochem Biophys Res Commun 1996;228:474-479.
6. Deyashiki Y, Ogasawara A, Nakayama T, Nakanishi M, Miyabe Y, Sato K and Hara A. Molecular cloning of two human liver 3a-hydroxysteroid/ dihydrodiol dehydrogenase isoenzymes that are identical with chlordecone reductase and bile-acid binder. Biochem J 1994;299:545-552.
7. Khanna M, Qin KN, Wang RW and Cheng KC. Substrate specificity, gene structure, and tissue-specific distribution of multiple human 3a-hydroxysteroid dehydrogenases. J Biol Chem 1995;270:20162-20168.
8. Lin HK, Jez JM, Schlegel BP, Peehl DM, Pachter JA and Penning TM. Expression and character-characterization of recombinant type 2 3a-hydroxysteroid dehydrogenase (HSD) from human pros tate:demonstration of bifunctional 3a/17b-HSD activity and cellular distribution. Mol Endocrinol 1997;11:1971-1984.
9. Dufort I, Rheault P, Huang XF, Soucy P and Luu-The V. Characteristics of a highly labile human type 5 17á-hydroxysteroid dehydrogenase. Endocrinology 1999;140:568-574.
10. Steckelbroeck S, Jin Y, Gopishetty S, Oyesanmi B and Penning TM. Human cytosolic 3a-hydroxysteroid dehydrogenases of the aldo-keto reductase superfamily display significant 3b-hydroxysteroid dehydrogenase activity:implications for steroid hormone metabolism and action. J Biol Chem 2004;279:10784-10795.
11. Penning TM, Burczynski ME, Jez JM, Hung CF, Lin HK, Ma H, Moore M, Palackal N and Ratnam K. Human 3a-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily:functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem J 2000;351:67-77.
12. 2 11-ketoreductase activity. J Biochem (Tokyo) 1998;124:940-946.
13. Penning TM, Steckelbroeck S, Bauman DR, Miller MW, Jin Y, Peehl DM, Fung KM and Lin HK. Aldo-keto reductase (AKR) 1C3:Role in prostate disease and the development of specific inhibitors. Mol Cell Endocrinol 2006;248:182-191.
14. Lin HK, Steckelbroeck S, Fung KM, Jones AN and Penning TM. Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3a-hydroxysteroid dehydrogenase/ type 5 17b-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate. Steroids 2004;69:795-801.
15. Rizner TL, Smuc T, Rupreht R, Sinkovec J and Penning TM. AKR1C1 and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer. Mol Cell Endocrinol 2006;248:126-135.
16. Fung KM, Samara ENS, Wong C, Metwalli A, Krlin R, Bane B, Liu CZ, Yang JT, Pitha JT, Culkin DJ, Kropp BP, Penning TM and Lin HK. Increased expression of type 2 3a-hydroxysteroid dehydrogenase/type 5 17b-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma. Endocr Relat Cancer 2006;13:169-180.
17. Ashley RA, Yu Z, Fung KM, Frimberger D, Kropp BP, Penning TM and Lin HK. Developmental evaluation of aldo-keto reductase 1C3 expression in the cryptorchid testis. Urology 2010;76:67-72.
18. Azzarello J, Fung KM and Lin HK. Tissue distribution of human AKR1C3 and rat homolog in adult genitourinary system. J Histochem Cytochem 2008;56:853-861.
19. Lewis MJ, Wiebe JP and Heathcote JG. Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma. BMC Cancer 2004;4:27.
20. Ito K, Utsunomiya H, Suzuki T, Saitou S, Akahira J, Okamura K, Yaegashi N and Sasano H. 17b-hydroxysteroid dehydrogenases in human endometrium and its disorders. Mol Cell Endocrinol 2006;248:136-140.
21. Nakamura Y, Suzuki T, Nakabayashi M, Endoh M, Sakamoto K, Mikami Y, Moriya T, Ito A, Takahashi S, Yamada S, Arai Y and Sasano H. In situ androgen producing enzymes in human prostate cancer. Endocr Relat Cancer 2005;12:101-107.
22. Stanbrough M, Bubley G, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG and Balk SP. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006;66:2815-2825.
23. Wako K, Kawasaki T, Yamana K, Suzuki K, Jiang S, Umezu H, Nishiyama T, Takahashi K, Hamakubo T, Kodama T and Naito M. Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer. J Clin Pathol 2008;61:448-454.
24. Mahadevan D, DiMento J, Croce KD, Riley C, George B, Fuchs D, Mathews T, Wilson C and Lobell M. Transcriptosome and serum cytokine profiling of an atypical case of myelodysplastic syndrome with progression to acute myelogenous leukemia. Am J Hematol 2006;81:779-786.
25. Lan Q, Mumford JL, Shen M, Demarini DM, Bonner MR, He X, Yeager M, Welch R, Chanock S, Tian L, Chapman RS, Zheng T, Keohavong P, Caporaso N and Rothman N. Oxidative damage-related genes AKR1C3 and OGG1 modulate risks for lung cancer due to exposure to PAH-rich coal combustion emissions. Carcinogenesis 2004;25:2177-2181.
26. Miller VL, Lin HK, Murugan P, Fan M, Penning TM, Brame LS, Yang Q and Fung KM. Aldo-keto reductase family 1 member C3 (AKR1C3) is expressed in adenocarcinoma and squamous cell carcinoma but not small cell carcinoma. Int J Clin Exp Pathol 2012;5:278-289.
27. Azzarello JT, Lin HK, Gherezghiher A, Zakharov V, Yu Z, Kropp BP, Culkin DJ, Penning TM and Fung KM. Expression of AKR1C3 in renal cell carcinoma, papillary urothelial carcinoma, and Wilms' tumor. Int J Clin Exp Pathol 2009;3:147-155.
28. Park AL, Lin HK, Yang Q, Sing CW, Fan M, Mapstone TB, Gross NL, Gumerlock MK, Martin MD, Rabb CH and Fung KM. Differential expression of type 2 3a/type 5 17b-hydroxysteroid dehydrogenase (AKR1C3) in tumors of the central nervous system. Int J Clin Exp Pathol 2010;3:743-754.
29. Hamilton SR and Aaltonen LA. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System. Lyon:IARC Press, 2000.
30. Kaltsas GA, Besser GM and Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 2004;25:458-511.
31. Zakharov V, Lin HK, Azzarello J, McMeekin S, Moore KN, Penning TM and Fung KM. Suppressed expression of type 2 3a/type 5 17b-hydroxysteroid dehydrogenase (AKR1C3) in endometrial hyperplasia and carcinoma. Int J Clin Exp Pathol 2010;3:608-617.
32. Han B, Li S, Song D, Poisson-Pare D, Liu G, Luu-The V, Ouellet J, Labrie F and Pelletier G. Expression of 17b-hydroxysteroid dehydrogenase type 2 and type 5 in breast cancer and adjacent non-malignant tissue:a correlation to clinicopathological parameters. J Steroid Biochem Mol Biol 2008;112:194-200.